Core Viewpoint - The Hong Kong stock market for innovative drugs continues to decline, with the Hang Seng Index falling below the six-month moving average, indicating ongoing adjustments in the sector [1][3]. Market Performance - On December 9, the Hong Kong innovative drug ETF (520880) experienced a decline of 1.99%, marking two consecutive days of losses, with a trading volume of 283 million yuan [1]. - Major stocks within the ETF saw significant declines, including Kangfang Biotech down 4%, Sanofi Biotech down 3.63%, and Innovent Biologics down 1.4% [1]. Investment Opportunities - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets, as the index has retraced over 18% since early September, indicating a sufficient adjustment and risk release [3]. - There are positive signals in the funding landscape, with over 56 million yuan net subscriptions for the innovative drug ETF on the previous day, the highest in nearly a month, indicating strong buying interest [4]. Policy Developments - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [5]. Business Development - Kelun-Biotech has granted exclusive rights to Crescent for the development of ADC drug SKB105 outside Greater China, along with exclusive rights for CR-001 bispecific antibody in Greater China, which includes an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [6]. - Analysts recommend focusing on innovative drug companies with rich pipeline layouts, high potential single products, and leading technology platforms [6]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten holdings accounting for over 72% of the index, showcasing the strength of the innovative drug sector [7]. - The ETF has a total market value of 2.142 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 458 million yuan since its inception [7].

Core Insights - Kolon Biotech and Crescent Biopharma have established a strategic partnership, with Kolon granting Crescent rights to its ADC drug SKB105 outside of China, potentially generating over $1.3 billion in licensing revenue [2][3] - The collaboration includes the development of single-agent therapies for both SKB105 and Crescent's PD-1/VEGF bispecific antibody CR-001, as well as evaluating the combination therapy of CR-001 with SKB105 [2][3] Company Summaries - Kolon Biotech will receive an upfront payment of $80 million from Crescent, with eligibility for up to $1.25 billion in milestone payments and tiered royalties based on SKB105's net sales [3] - Crescent will pay Kolon an upfront fee of $20 million, with potential milestone payments of $30 million and tiered royalties based on CR-001's net sales [3] Industry Context - The partnership enhances Kolon Biotech's differentiated oncology pipeline and supports the global development of SKB105 [4] - The PD-1/VEGF bispecific antibody market is a hot area for development, with Chinese companies leading in progress and efficacy, attracting interest from multinational pharmaceutical companies [5] - The combination of ADCs with PD-1/VEGF bispecific antibodies is becoming a clear technical direction in the pharmaceutical industry, as evidenced by other collaborations in the sector [5]